Symptomatic MERS-CoV Infection Reduces the Risk of Future COVID-19 Disease; a Retrospective Cohort Study

Overview

Journal BMC Infect Dis

Publisher Biomed Central

Specialty Infectious Diseases

Date 2023 Nov 4

PMID 37924004

Authors

Aiman El-Saed

Fatmah Othman

Henry Baffoe-Bonnie

Rawabi Almulhem

Muayed Matalqah

Latifah Alshammari

Majid M Alshamrani

Affiliations

Soon will be listed here.

Abstract

Background: The general human immune responses similarity against different coronaviruses may reflect some degree of cross-immunity, whereby exposure to one coronavirus may confer partial immunity to another. The aim was to determine whether previous MERS-CoV infection was associated with a lower risk of subsequent COVID-19 disease and its related outcomes.

Methods: We conducted a retrospective cohort study among all patients screened for MERS-CoV at a tertiary care hospital in Saudi Arabia between 2012 and early 2020. Both MERS-CoV positive and negative patients were followed up from early 2020 to September 2021 for developing COVID-19 infection confirmed by RT-PCR testing.

Results: A total of 397 participants followed for an average 15 months during COVID-19 pandemic (4.9 years from MERS-CoV infection). Of the 397 participants, 93 (23.4%) were positive for MERS-CoV at baseline; 61 (65.6%) of the positive cases were symptomatic. Out of 397, 48 (12.1%) participants developed COVID-19 by the end of the follow-up period. Cox regression analysis adjusted for age, gender, and major comorbidity showed a marginally significant lower risk of COVID-19 disease (hazard ratio = 0.533, p = 0.085) and hospital admission (hazard ratio = 0.411, p = 0.061) in patients with positive MERS-CoV. Additionally, the risk of COVID-19 disease was further reduced and became significant in patients with symptomatic MERS-CoV infection (hazard ratio = 0.324, p = 0.034) and hospital admission (hazard ratio = 0.317, p = 0.042).

Conclusions: The current findings may indicate a partial cross-immunity, where patients with symptomatic MERS-CoV have a lower risk of future COVID-19 infection and related hospitalization. The present results may need further examination nationally using immunity markers.

Citing Articles

Seasonal human coronavirus humoral responses in AZD1222 (ChaAdOx1 nCoV-19) COVID-19 vaccinated adults reveal limited cross-immunity.

Stanley A, Aksyuk A, Wilkins D, Green J, Lan D, Shoemaker K Front Immunol. 2024; 15:1401728.

PMID: 38827749 PMC: 11143795. DOI: 10.3389/fimmu.2024.1401728.

Back to the Future: Immune Protection or Enhancement of Future Coronaviruses.

Bartels M, Sala Sole E, Sauerschnig L, Rijkers G Microorganisms. 2024; 12(3).

PMID: 38543668 PMC: 10975256. DOI: 10.3390/microorganisms12030617.

References

Aran D, Beachler D, Lanes S, Overhage J . Prior presumed coronavirus infection reduces COVID-19 risk: A cohort study. J Infect. 2020; 81(6):923-930. PMC: 7590640. DOI: 10.1016/j.jinf.2020.10.023. View

Omrani A, Shalhoub S . Middle East respiratory syndrome coronavirus (MERS-CoV): what lessons can we learn?. J Hosp Infect. 2015; 91(3):188-96. PMC: 7114843. DOI: 10.1016/j.jhin.2015.08.002. View

Balkhy H, Alenazi T, Alshamrani M, Baffoe-Bonnie H, Arabi Y, Hijazi R . Description of a Hospital Outbreak of Middle East Respiratory Syndrome in a Large Tertiary Care Hospital in Saudi Arabia. Infect Control Hosp Epidemiol. 2016; 37(10):1147-55. PMC: 7113028. DOI: 10.1017/ice.2016.132. View

Drosten C, Meyer B, Muller M, Corman V, Al-Masri M, Hossain R . Transmission of MERS-coronavirus in household contacts. N Engl J Med. 2014; 371(9):828-35. DOI: 10.1056/NEJMoa1405858. View

Corman V, Albarrak A, Omrani A, Albarrak M, Farah M, Almasri M . Viral Shedding and Antibody Response in 37 Patients With Middle East Respiratory Syndrome Coronavirus Infection. Clin Infect Dis. 2015; 62(4):477-483. PMC: 7108065. DOI: 10.1093/cid/civ951. View

Alenazi T, Al Arbash H, El-Saed A, Alshamrani M, Baffoe-Bonnie H, Arabi Y . Identified Transmission Dynamics of Middle East Respiratory Syndrome Coronavirus Infection During an Outbreak: Implications of an Overcrowded Emergency Department. Clin Infect Dis. 2017; 65(4):675-679. PMC: 7108118. DOI: 10.1093/cid/cix352. View

Alshukairi A, Zhao J, Al-Mozaini M, Wang Y, Dada A, Baharoon S . Longevity of Middle East Respiratory Syndrome Coronavirus Antibody Responses in Humans, Saudi Arabia. Emerg Infect Dis. 2021; 27(5). PMC: 8084512. DOI: 10.3201/eid2705.204056. View

Ashour H, Elkhatib W, Rahman M, Elshabrawy H . Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks. Pathogens. 2020; 9(3). PMC: 7157630. DOI: 10.3390/pathogens9030186. View

Cherry J . The chronology of the 2002-2003 SARS mini pandemic. Paediatr Respir Rev. 2004; 5(4):262-9. PMC: 7106085. DOI: 10.1016/j.prrv.2004.07.009. View

10.

Zhang Y, Li B, Ning B . The Comparative Immunological Characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 Coronavirus Infections. Front Immunol. 2020; 11:2033. PMC: 7457039. DOI: 10.3389/fimmu.2020.02033. View

11.

Choe P, Perera R, Beom Park W, Song K, Bang J, Kim E . MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015. Emerg Infect Dis. 2017; 23(7):1079-1084. PMC: 5512479. DOI: 10.3201/eid2307.170310. View

12.

Khan A, Alahmari A, Almuzaini Y, Alamri F, Alsofayan Y, Aburas A . Potential Cross-Reactive Immunity to COVID-19 Infection in Individuals With Laboratory-Confirmed MERS-CoV Infection: A National Retrospective Cohort Study From Saudi Arabia. Front Immunol. 2021; 12:727989. PMC: 8484965. DOI: 10.3389/fimmu.2021.727989. View

13.

Filip R, Gheorghita Puscaselu R, Anchidin-Norocel L, Dimian M, Savage W . Global Challenges to Public Health Care Systems during the COVID-19 Pandemic: A Review of Pandemic Measures and Problems. J Pers Med. 2022; 12(8). PMC: 9409667. DOI: 10.3390/jpm12081295. View

14.

Long Q, Tang X, Shi Q, Li Q, Deng H, Yuan J . Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020; 26(8):1200-1204. DOI: 10.1038/s41591-020-0965-6. View

15.

Sariol A, Perlman S . Lessons for COVID-19 Immunity from Other Coronavirus Infections. Immunity. 2020; 53(2):248-263. PMC: 7359787. DOI: 10.1016/j.immuni.2020.07.005. View

16.

Vkovski P, Kratzel A, Steiner S, Stalder H, Thiel V . Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2020; 19(3):155-170. PMC: 7592455. DOI: 10.1038/s41579-020-00468-6. View

17.

Zhao J, Alshukairi A, Baharoon S, Ahmed W, Bokhari A, Nehdi A . Recovery from the Middle East respiratory syndrome is associated with antibody and T-cell responses. Sci Immunol. 2017; 2(14). PMC: 5576145. DOI: 10.1126/sciimmunol.aan5393. View

18.

Liu W, Zhao M, Liu K, Xu K, Wong G, Tan W . T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV. Antiviral Res. 2016; 137:82-92. PMC: 7113894. DOI: 10.1016/j.antiviral.2016.11.006. View

19.

Borrega R, Nelson D, Koval A, Bond N, Heinrich M, Rowland M . Cross-Reactive Antibodies to SARS-CoV-2 and MERS-CoV in Pre-COVID-19 Blood Samples from Sierra Leoneans. Viruses. 2021; 13(11). PMC: 8625389. DOI: 10.3390/v13112325. View

20.

Sinderewicz E, Czelejewska W, Jezierska-Wozniak K, Staszkiewicz-Chodor J, Maksymowicz W . Immune Response to COVID-19: Can We Benefit from the SARS-CoV and MERS-CoV Pandemic Experience?. Pathogens. 2020; 9(9). PMC: 7559562. DOI: 10.3390/pathogens9090739. View